BTIG Research Cuts Caris Life Sciences (NASDAQ:CAI) Price Target to $38.00

Caris Life Sciences (NASDAQ:CAI) had its price objective cut by BTIG Research from $45.00 to $38.00 in a report released on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other brokerages have also issued reports on CAI. Wall Street Zen lowered Caris Life Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Robert W. Baird increased their price objective on Caris Life Sciences from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Friday. Weiss Ratings reissued a “sell (d)” rating on shares of Caris Life Sciences in a research report on Monday, December 29th. Canaccord Genuity Group upped their target price on shares of Caris Life Sciences from $28.00 to $30.00 and gave the stock a “hold” rating in a research report on Monday, December 22nd. Finally, Evercore set a $38.00 price target on shares of Caris Life Sciences in a research report on Monday, January 5th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $33.50.

Caris Life Sciences Trading Up 4.7%

NASDAQ:CAI opened at $20.14 on Friday. The stock has a 50-day moving average of $24.42. The stock has a market cap of $5.68 billion and a PE ratio of -43.78. The company has a debt-to-equity ratio of 0.79, a quick ratio of 9.36 and a current ratio of 9.93. Caris Life Sciences has a 12 month low of $17.15 and a 12 month high of $42.50.

Caris Life Sciences (NASDAQ:CAI) last released its quarterly earnings results on Thursday, February 26th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.27. The company had revenue of $292.89 million during the quarter, compared to the consensus estimate of $281.00 million. During the same period in the previous year, the company earned ($1.73) earnings per share. Caris Life Sciences’s quarterly revenue was up 125.4% on a year-over-year basis.

Insiders Place Their Bets

In related news, insider Luke Thomas Power sold 62,250 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $26.58, for a total value of $1,654,605.00. Following the transaction, the insider directly owned 99,571 shares of the company’s stock, valued at approximately $2,646,597.18. This represents a 38.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 7.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of CAI. Global Retirement Partners LLC increased its holdings in Caris Life Sciences by 99,900.0% in the 4th quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock worth $27,000 after buying an additional 999 shares in the last quarter. Olistico Wealth LLC purchased a new stake in shares of Caris Life Sciences during the 4th quarter valued at about $31,000. MetLife Investment Management LLC grew its stake in shares of Caris Life Sciences by 84.0% in the fourth quarter. MetLife Investment Management LLC now owns 1,654 shares of the company’s stock worth $45,000 after acquiring an additional 755 shares during the period. Aster Capital Management DIFC Ltd purchased a new position in shares of Caris Life Sciences during the fourth quarter valued at approximately $67,000. Finally, Federated Hermes Inc. bought a new position in Caris Life Sciences during the fourth quarter valued at approximately $81,000.

Key Headlines Impacting Caris Life Sciences

Here are the key news stories impacting Caris Life Sciences this week:

• Positive Sentiment: Q4 beat and strong revenue growth — CAI reported GAAP EPS of $0.28 (well above estimates) and Q4 revenue of ~$293M, up ~125% YoY, demonstrating accelerating top‑line momentum. Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
• Positive Sentiment: Major interim Achieve 1 readout — The company announced interim data showing Caris Detect (WGS + AI) had superior sensitivity and specificity vs. methylation‑based approaches, a milestone for its MCED launch and long‑term growth potential in early cancer detection. Caris Life Sciences Completes Interim Readout of Achieve 1 Study
• Positive Sentiment: 2026 revenue guidance reaffirmed/raised — Management guided full‑year 2026 revenue to roughly $1.0B–$1.02B (above consensus), supporting sustained growth expectations as profiling services and new product launches scale. Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
• Positive Sentiment: Analyst support — Robert W. Baird initiated coverage / raised its price target (to $28 with an Outperform stance), bringing new institutional attention that can boost demand for the stock. Baird Initiates Coverage of Caris Life Sciences, Inc. (CAI) with an Outperform Rating
• Positive Sentiment: Product enhancement — Caris added an AI‑powered breast cancer signature to its Caris Molecular Tumor Board Report, expanding clinical utility and potential revenue per case in precision oncology. Caris Life Sciences (CAI) Adds New AI-powered Breast Cancer Signature to its Report
• Neutral Sentiment: Mixed analyst moves — BTIG lowered its price target from $45 to $38 but maintained a Buy rating; still bullish but the cut tempers some upside expectations. BTIG price target note
• Neutral Sentiment: Further reading / call details — The Q4 earnings call transcript and additional materials are available for investors who want management commentary on Caris Detect commercialization timing and margin cadence. Caris Life Sciences, Inc. (CAI) Q4 2025 Earnings Call Transcript

Caris Life Sciences Company Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.